OCUL insider trading
NasdaqGM HealthcareOCULAR THERAPEUTIX, INC: insider trade history from SEC Form 4 filings.
About OCULAR THERAPEUTIX, INC
Ocular Therapeutix, Inc., a biopharmaceutical company, engages in the development and commercialization of therapies for retinal diseases and other eye conditions using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis. It is also developing AXPAXLI, an axitinib intravitreal hydrogel that is in phase 3 clinical trials for the treatment of wet age-related macular degeneration and non-proliferative diabetic retinopathy; OTX-TIC, a travoprost intracameral hydrogel, which has completed phase 2 clinical trials for the treatment of open-angle glaucoma or ocular hypertension. The company has a license agreement and collaboration with AffaMed Therapeutics Limited for the development and commercialization of DEXTENZA and OTX-TIC. Ocular Therapeutix, Inc. was incorporated in 2006 and is headquartered in Bedford, Massachusetts.
Company website: www.ocutx.com
OCUL insider activity at a glance
FilingIQ tracks 263 insider transactions for OCUL in filings since Feb 4, 2015. The most recent transaction is dated Aug 31, 2026.
Across the full history, 69 open-market purchases
and 88 open-market sales
were filed under transaction codes P and S respectively. Compensatory share awards
(code A) and option exercises (code M) are tracked separately and not counted here.
The average FilingIQ composite score on OCUL insider trades is 53.6/100, produced by FilingIQ's multi-factor Form 4 model. Model framework documented at methodology.
Latest OCUL Form 4 filings
Most recent disclosures. Sign up to filter by score, transaction code, or insider role.
Other Healthcare tickers with recent insider activity
Frequently asked
- How many insider trades does FilingIQ track for OCUL?
- FilingIQ tracks 263 Form 4 insider transactions for OCUL (OCULAR THERAPEUTIX, INC), covering filings from Feb 4, 2015 onwards. 7 of those are dated within the last 90 days.
- Are OCUL insiders net buyers or net sellers?
- Across the full Form 4 history for OCUL, 69 transactions (26%) were open-market purchases and 88 (33%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.
- Where does OCUL insider data come from?
- Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ normalises insider identity across reporting variations and scores discretionary open-market purchases and sales on its multi-factor composite model.
- What sector is OCUL in?
- OCULAR THERAPEUTIX, INC (OCUL) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $1.89B.
Methodology & sources
Every OCUL insider transaction shown on FilingIQ is parsed directly from a public SEC Form 4 XML filing. Insider identity is normalised across reporting variants (CIK changes, name spellings, related-party indirect holdings). The FilingIQ composite score is documented in full on the team page and algo disclosure. Not investment advice; see disclaimer.